https://www.pharmaradar360.com/article/makinde-others-to-grace-psn-oyo-2026-world-pharmacists-day-f74cb2bf371b0c73PharmaRadar360en2026-09-13T15:32:38.000ZMakinde, others to grace PSN Oyo 2026 World Pharmacists Dayhttps://www.pharmaradar360.com/article/dbvt-slides-as-dbv-technologies-leads-european-biotech-declines-bfb64ba5124bdf18PharmaRadar360en2026-09-13T15:05:00.000ZDBVT Slides As DBV Technologies Leads European Biotech Declineshttps://www.pharmaradar360.com/article/how-to-trade-this-2-billion-biotech-name-moving-quickly-toward-profit-e72df0c44deb6bd8PharmaRadar360en2026-09-13T15:00:00.000ZHow to Trade This $2 Billion Biotech Name Moving Quickly Toward Profithttps://www.pharmaradar360.com/article/3-small-cap-biotechs-with-binary-catalysts-on-the-calendar-451f0e34f912ed8ePharmaRadar360en2026-09-13T14:52:31.000Z3 Small-Cap Biotechs With Binary Catalysts on the Calendarhttps://www.pharmaradar360.com/article/3-small-cap-biotechs-with-binary-catalysts-on-the-calendar-3c11057fc1f82d23PharmaRadar360en2026-09-13T14:50:00.000Z3 Small-Cap Biotechs With Binary Catalysts on the Calendarhttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-insider-trading-activity-2026-249623a1453a3bf2PharmaRadar360en2026-09-13T14:21:32.000ZVeraxa Biotech (VRXA) Insider Trading Activity 2026https://www.pharmaradar360.com/article/pharma-drugs-from-other-states-emerge-as-new-challenge-for-punjab-police-964229af63a04d03PharmaRadar360en2026-09-13T13:58:50.000ZPharma drugs from other states emerge as new challenge for Punjab policehttps://www.pharmaradar360.com/article/yesterday-when-i-was-young-how-grief-and-music-motivate-this-hong-kong-biotech-s-6bbb76fd500ed8c5PharmaRadar360en2026-09-13T12:33:35.000Z“Yesterday, when I was young”: how grief and music motivate this Hong Kong biotech start-up CEOhttps://www.pharmaradar360.com/article/novartis-stock-stabilizes-after-trial-setbacks-as-investor-pushes-for-board-shak-91c49459cb9bde0dPharmaRadar360en2026-09-13T12:19:52.000ZNovartis stock stabilizes after trial setbacks as investor pushes for board shake-uphttps://www.pharmaradar360.com/article/roivant-sciences-diverse-exposure-to-biotech-niches-through-vants-nasdaq-roiv-f755b46573c262a0PharmaRadar360en2026-09-13T11:30:08.000ZRoivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV)https://www.pharmaradar360.com/article/punjab-sees-shift-in-drug-trade-heroin-availability-falls-pharmaceutical-narcoti-3c356b6a4ec030fcPharmaRadar360en2026-09-13T11:19:00.000ZPunjab sees shift in drug trade: Heroin availability falls, pharmaceutical narcotics emerge as major challengehttps://www.pharmaradar360.com/article/heroin-supply-falls-in-punjab-but-pharma-drugs-from-other-states-emerge-as-new-c-553dd4232e825186PharmaRadar360en2026-09-13T11:13:13.000ZHeroin supply falls in Punjab, but pharma drugs from other states emerge as new challenge: Punjab Policehttps://www.pharmaradar360.com/article/etfs-investing-in-hebei-changshan-biochemical-pharmaceutical-co-ltd-class-a-stoc-12d05f5761881b7dPharmaRadar360en2026-09-13T11:12:17.000ZETFs Investing in Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/india-s-patent-office-issues-draft-guidelines-for-pharma-biotech-patents-f5ea25ff845c0d58PharmaRadar360en2026-09-13T10:20:22.000ZIndia's patent office issues draft guidelines for pharma biotech patentshttps://www.pharmaradar360.com/article/kardigan-funded-precision-cardiology-offers-more-than-pipeline-diversification-903862474345a45ePharmaRadar360en2026-09-13T10:10:26.000ZKardigan: Funded Precision Cardiology Offers More Than Pipeline Diversificationhttps://www.pharmaradar360.com/article/a-breakthrough-cancer-vaccine-fueled-a-biotech-rally-can-it-last-16c0e73db8d97a9aPharmaRadar360en2026-09-13T10:08:25.000ZA Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?https://www.pharmaradar360.com/article/aan-ahs-issue-updated-guideline-on-migraine-prevention-atogepant-meets-end-point-fba9ebb04f21030bPharmaRadar360en2026-09-13T10:00:00.000ZAAN, AHS Issue Updated Guideline on Migraine Prevention, Atogepant Meets End Points in Phase 3 Trial, Trientine Enters Phase 3 Trialhttps://www.pharmaradar360.com/article/scientist-challenges-pharmaceutical-ceo-7d668b086603b6daPharmaRadar360en2026-09-13T09:34:19.000Z▶️ Scientist challenges pharmaceutical CEOhttps://www.pharmaradar360.com/article/mirum-s-azure-3-trial-a-new-switch-strategy-in-chronic-hepatitis-d-7e2f82ccd93e8fa1PharmaRadar360en2026-09-13T09:17:51.000ZMirum’s AZURE-3 Trial: A New Switch Strategy in Chronic Hepatitis Dhttps://www.pharmaradar360.com/article/pharmacists-and-civic-groups-in-south-korea-rally-to-block-telemedicine-drug-del-b3f335563b1d4740PharmaRadar360en2026-09-13T08:37:00.000ZPharmacists and civic groups in South Korea rally to block telemedicine drug delivery expansion - CHOSUNBIZhttps://www.pharmaradar360.com/article/kush-choksi-promoted-to-assistant-vice-president-business-development-at-strides-67d859a68cdf70fcPharmaRadar360en2026-09-13T08:25:55.000ZKush Choksi Promoted to Assistant Vice President – Business Development at Strides Pharmahttps://www.pharmaradar360.com/article/russians-attack-ukraine-s-second-largest-pharmaceutical-warehouse-twice-e64594d4abfd7904PharmaRadar360en2026-09-13T08:13:00.000ZRussians attack Ukraine's second-largest pharmaceutical warehouse twicehttps://www.pharmaradar360.com/article/merali-family-acquires-stake-in-sh330-million-mombasa-glass-plant-534ff22c2cb25d15PharmaRadar360en2026-09-13T08:06:33.000ZMerali family acquires stake in Sh330 million Mombasa glass planthttps://www.pharmaradar360.com/article/california-state-teachers-retirement-system-grows-holdings-in-teva-pharmaceutica-401670e366181271PharmaRadar360en2026-09-13T08:06:09.000ZCalifornia State Teachers Retirement System Grows Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/indian-patent-office-releases-draft-pharma-and-biotech-patent-rules-745c2dc8449c8b47PharmaRadar360en2026-09-13T08:04:40.000ZIndian Patent Office Releases Draft Pharma and Biotech Patent Ruleshttps://www.pharmaradar360.com/article/ris-rez-reduced-risk-of-death-by-54-versus-topotecan-in-patients-with-relapsed-s-bc1325534320d150PharmaRadar360en2026-09-13T08:00:00.000ZRis-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in Chinahttps://www.pharmaradar360.com/article/mcaz-remedica-medicine-recall-zimbabwe-for-nifedipine-levodopa-4a21d23560bf1ceePharmaRadar360en2026-09-13T07:29:52.000ZMCAZ: Remedica Medicine Recall Zimbabwe for Nifedipine, Levodopahttps://www.pharmaradar360.com/article/mitapivat-just-rewrote-the-treatment-floor-for-transfusion-dependent-thalassaemi-0e1aeb228fea5f5fPharmaRadar360en2026-09-13T07:28:29.000ZMitapivat Just Rewrote the Treatment Floor for Transfusion-Dependent Thalassaemia, Here’s What the ENERGIZE-T Data Actually Meanhttps://www.pharmaradar360.com/article/indian-patent-office-proposes-new-guidelines-for-pharma-patent-examination-5171aedfc3e70ab9PharmaRadar360en2026-09-13T07:21:44.000ZIndian Patent Office proposes new guidelines for pharma patent examinationhttps://www.pharmaradar360.com/article/tam-peli-meets-primary-endpoint-for-relapsed-small-cell-lung-cancer-in-phase-iii-ac7af87a08f589adPharmaRadar360en2026-09-13T06:38:27.000ZTam-Peli meets primary endpoint for relapsed small-cell lung cancer in phase III trialhttps://www.pharmaradar360.com/article/iza-bren-2-5-mg-kg-dose-advances-to-phase-3-in-egfr-mutated-nsclc-70789e99d842e835PharmaRadar360en2026-09-13T06:38:27.000ZIza-bren 2.5 mg/kg dose advances to Phase 3 in EGFR-mutated NSCLChttps://www.pharmaradar360.com/article/j-j-exits-laa-closure-market-sells-laminar-program-to-jaguar-laa-77731cf65f918dd3PharmaRadar360en2026-09-13T06:38:27.000ZJ&J Exits LAA Closure Market, Sells Laminar Program to Jaguar LAAhttps://www.pharmaradar360.com/article/aurobindo-s-curateq-biologics-reports-positive-phase-3-results-for-omalizumab-bi-65c6bb10b421292ePharmaRadar360en2026-09-13T06:07:52.000ZAurobindo's CuraTeQ Biologics Reports Positive Phase 3 Results for Omalizumab Biosimilarhttps://www.pharmaradar360.com/article/ntla-stock-surges-35-overnight-retail-mood-peaks-ahead-of-first-ever-phase-3-rea-d5beb93535a18e5ePharmaRadar360en2026-09-13T05:49:54.000ZNTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapyhttps://www.pharmaradar360.com/article/antibody-drug-combination-falls-short-in-first-line-pd-l1-high-metastatic-lung-c-355a95d6d905ce35PharmaRadar360en2026-09-13T04:02:58.000ZAntibody-Drug Combination Falls Short in First-Line PD-L1-High Metastatic Lung Cancer Trialhttps://www.pharmaradar360.com/article/holiferm-and-organica-uk-combine-to-build-integrated-biotech-and-sustainable-pro-326ddd6adcb0a06ePharmaRadar360en2026-09-13T02:17:04.000ZHoliferm And Organica UK Combine To Build Integrated Biotech And Sustainable Products Platformhttps://www.pharmaradar360.com/article/merck-gilead-s-failed-trodelvy-lung-cancer-trial-shows-better-china-results-76c37bd818cc89c6PharmaRadar360en2026-09-13T01:44:19.000ZMerck, Gilead’s failed Trodelvy lung cancer trial shows better China resultshttps://www.pharmaradar360.com/article/bhushan-malpure-elevated-to-head-of-marketing-at-cipla-9e97a17d55f1f388PharmaRadar360en2026-09-13T01:26:14.000ZBhushan Malpure elevated to Head of Marketing at Ciplahttps://www.pharmaradar360.com/article/polyester-thermal-ribbon-material-market-forecast-to-2035-driven-by-coding-and-m-423a025c3eff05f6PharmaRadar360en2026-09-13T00:41:22.000ZPolyester Thermal Ribbon Material Market Forecast to 2035, Driven by Coding and Marking Demand in Food and Pharmaceutical Packaginghttps://www.pharmaradar360.com/article/sls-stock-hits-over-3-year-high-as-aml-drug-trial-nears-final-readout-wall-stree-d690b1c596b74875PharmaRadar360en2026-09-13T00:37:31.000ZSLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upsidehttps://www.pharmaradar360.com/article/roche-s-cancer-drug-cut-death-risk-54-in-a-phase-iii-trial-aa806bf235967344PharmaRadar360en2026-09-13T00:13:14.000ZRoche’s cancer drug cut death risk 54% in a phase III trialhttps://www.pharmaradar360.com/article/roche-s-collaborator-medilink-announces-phase-iii-data-for-tam-peli-showing-sign-59cd66eaa83f33abPharmaRadar360en2026-09-13T00:00:00.000ZRoche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancerhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-41783f9f4fe26fa5PharmaRadar360en2026-09-13T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-8a1d864a54a236f9PharmaRadar360en2026-09-13T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-a1f50862dd647aedPharmaRadar360en2026-09-13T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-cf79c90c168f6560PharmaRadar360en2026-09-13T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-fca71bb67ffc6cf4PharmaRadar360en2026-09-13T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-016ed0daa4a382faPharmaRadar360en2026-09-13T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-90999b8b729a522fPharmaRadar360en2026-09-13T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-156eee7f0569b172PharmaRadar360en2026-09-13T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-e666d6c5cf38bd2fPharmaRadar360en2026-09-13T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-6419ab92143f43ecPharmaRadar360en2026-09-13T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-bcdfd5f502ec0627PharmaRadar360en2026-09-13T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-164ee15f02b3d2e2PharmaRadar360en2026-09-13T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-fe6ef9fbd454d7d9PharmaRadar360en2026-09-13T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-853c14e9c637dcb2PharmaRadar360en2026-09-13T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/transfascial-paraspinal-versus-conventional-open-posterior-pedicle-screw-fixatio-702e3f0c54fd95bcPharmaRadar360en2026-09-13T00:00:00.000ZTransfascial Paraspinal Versus Conventional Open Posterior Pedicle Screw Fixation for Thoracolumbar Fractures: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/when-fever-hides-fire-a-systematic-review-of-clinical-and-digital-approaches-to-3b1675982556c63dPharmaRadar360en2026-09-13T00:00:00.000ZWhen Fever Hides Fire: A Systematic Review of Clinical and Digital Approaches to Early Recognition of Pediatric Sepsishttps://www.pharmaradar360.com/article/integrated-clinical-biological-and-echocardiographic-factors-independently-assoc-d9399d45b2a33f73PharmaRadar360en2026-09-13T00:00:00.000ZIntegrated Clinical, Biological, and Echocardiographic Factors Independently Associated With In-Hospital Mortality in Infective Endocarditis: A Single-Centre Cohort Study From Moroccohttps://www.pharmaradar360.com/article/an-interpretable-machine-learning-technique-for-chronic-kidney-disease-diagnosis-a36eb0bcde8fec07PharmaRadar360en2026-09-13T00:00:00.000ZAn Interpretable Machine Learning Technique for Chronic Kidney Disease Diagnosis Using Clinical Datahttps://www.pharmaradar360.com/article/hemodynamic-assessment-of-different-septic-shock-resuscitation-strategies-a-comp-2e608c74e044dc35PharmaRadar360en2026-09-13T00:00:00.000ZHemodynamic assessment of different septic shock resuscitation strategies: a comparison of volume expansion versus norepinephrine administration, a prospective: Study protocolhttps://www.pharmaradar360.com/article/lt-b-gt-daily-versus-thrice-weekly-antituberculosis-therapy-for-drug-susceptible-0c5ecbecd8d647eaPharmaRadar360en2026-09-13T00:00:00.000Z<b>Daily versus thrice-weekly antituberculosis therapy for drug-susceptible pulmonary tuberculosis in adults: A systematic review and exploratory meta-analysis.</b>https://www.pharmaradar360.com/article/phenotypic-biofilm-formation-and-detection-of-biofilm-associated-genes-in-multid-36922277a1ca5ce2PharmaRadar360en2026-09-13T00:00:00.000ZPhenotypic biofilm formation and detection of biofilm-associated genes in multidrug-resistant Pseudomonas aeruginosa isolated from burn woundshttps://www.pharmaradar360.com/article/long-term-dupilumab-therapy-in-atopic-dermatitis-and-prurigo-nodularis-clinical-3093d0df68a96ae7PharmaRadar360en2026-09-13T00:00:00.000ZLong-term dupilumab therapy in atopic dermatitis and prurigo nodularis: clinical caseshttps://www.pharmaradar360.com/article/directions-for-improving-drug-provision-for-outpatients-with-diabetes-mellitus-c70325f08c56201ePharmaRadar360en2026-09-13T00:00:00.000ZDirections for improving drug provision for outpatients with diabetes mellitushttps://www.pharmaradar360.com/article/assessment-of-the-informativeness-of-the-snot-22-questionnaire-in-patients-with-4e9dcdbe265cd94aPharmaRadar360en2026-09-13T00:00:00.000ZAssessment of the informativeness of the SNOT-22 questionnaire in patients with drug-induced rhinitishttps://www.pharmaradar360.com/article/altered-pharmacokinetics-and-drug-dosing-in-obese-patients-a-traditional-review-e229aee037800092PharmaRadar360en2026-09-13T00:00:00.000ZALTERED PHARMACOKINETICS AND DRUG DOSING IN OBESE PATIENTS: A TRADITIONAL REVIEWhttps://www.pharmaradar360.com/article/ethical-ai-for-crisis-response-a-dynamic-policy-orchestrator-for-prescriptive-re-430bd70d0146756aPharmaRadar360en2026-09-13T00:00:00.000ZEthical AI for Crisis Response: A Dynamic Policy Orchestrator for Prescriptive Resilience in Pharmaceutical Supply Chainshttps://www.pharmaradar360.com/article/clinical-spectrum-and-electroencephalographic-correlation-in-subacute-sclerosing-22af5f8f19051f51PharmaRadar360en2026-09-13T00:00:00.000ZClinical Spectrum and Electroencephalographic Correlation in Subacute Sclerosing Panencephalitis: A Case Serieshttps://www.pharmaradar360.com/article/metabolic-consequences-of-vitamin-b6-deficiency-and-their-impact-on-lipid-metabo-27d51c561cbb492dPharmaRadar360en2026-09-13T00:00:00.000ZMetabolic Consequences of Vitamin B6 Deficiency and Their Impact on Lipid Metabolismhttps://www.pharmaradar360.com/article/subclinical-thyroid-dysfunction-when-to-treat-and-when-to-observe-a-comprehensiv-6559b87113af5617PharmaRadar360en2026-09-13T00:00:00.000ZSubclinical Thyroid Dysfunction: When to treat and when to observe. A comprehensive clinical reviewhttps://www.pharmaradar360.com/article/evaluating-public-acceptance-of-the-official-medicine-label-and-mobile-verificat-5ced3fb490225291PharmaRadar360en2026-09-13T00:00:00.000ZEvaluating public acceptance of the official medicine label and mobile verification application: a mixed-methods study applying the technology acceptance modelhttps://www.pharmaradar360.com/article/global-in-vitro-antimicrobial-susceptibility-profiles-of-mycobacterium-abscessus-fa989aa6b0f056d5PharmaRadar360en2026-09-13T00:00:00.000ZGlobal in vitro antimicrobial susceptibility profiles of Mycobacterium abscessus: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/determinants-of-adverse-drug-reaction-reporting-for-antimalarial-medicines-a-mix-7f511f27b1f61e6cPharmaRadar360en2026-09-13T00:00:00.000ZDeterminants of adverse drug reaction reporting for antimalarial medicines: a mixed-methods study among healthcare workers in ogun State Southwest Nigeriahttps://www.pharmaradar360.com/article/pre-surgical-immune-proteomic-profiles-in-serum-identify-inflamed-and-suppressed-4dc9fd98b8b9ad71PharmaRadar360en2026-09-13T00:00:00.000ZPre-surgical immune-proteomic profiles in serum identify inflamed and suppressed immune states associated with biochemical recurrence and PSA persistence in prostate cancerhttps://www.pharmaradar360.com/article/bibliometric-analysis-of-clinical-trials-on-tobacco-use-and-mental-health-resear-6825e6a1bf36f0a8PharmaRadar360en2026-09-13T00:00:00.000ZBibliometric Analysis of Clinical Trials on Tobacco Use and Mental Health: Research Trends and Implications for Oral Healthhttps://www.pharmaradar360.com/article/development-and-implementation-of-a-multi-attribute-quality-robustness-scoring-f-d6af0f220fb3e1ddPharmaRadar360en2026-09-13T00:00:00.000ZDevelopment and implementation of a multi-attribute quality robustness scoring framework for lifecycle management of diversified pharmaceutical portfolioshttps://www.pharmaradar360.com/article/the-impact-of-undiagnosed-child-adhd-on-family-outcomes-e35f9938b3a191a5PharmaRadar360en2026-09-13T00:00:00.000ZThe Impact of Undiagnosed Child ADHD on Family Outcomeshttps://www.pharmaradar360.com/article/meaning-centered-psychotherapy-for-existential-distress-and-demoralization-in-ad-0771ba15c32a9d1bPharmaRadar360en2026-09-13T00:00:00.000ZMeaning-Centered Psychotherapy for Existential Distress and Demoralization in Advanced Cancer: A Narrative Review of Clinical Evidence and Implications for End-of-Life Carehttps://www.pharmaradar360.com/article/quality-of-life-caregiver-burden-and-clinical-correlates-in-kabuki-syndrome-a-cr-4bd71d62b7107c31PharmaRadar360en2026-09-13T00:00:00.000ZQuality of life, caregiver burden, and clinical correlates in Kabuki syndrome: a cross-sectional observational studyhttps://www.pharmaradar360.com/article/establishing-non-fasting-lipid-reference-intervals-and-clinical-decision-limits-f81e8304eb1fab70PharmaRadar360en2026-09-13T00:00:00.000ZEstablishing non-fasting lipid reference intervals and clinical decision limits in a senegalese adult cohorthttps://www.pharmaradar360.com/article/exploring-the-interplay-between-interoception-and-dissociative-experiences-insig-6419b2b230094dd4PharmaRadar360en2026-09-13T00:00:00.000ZExploring the interplay between interoception and dissociative experiences: insights from a non-clinical populationhttps://www.pharmaradar360.com/article/influence-of-gingival-thickness-on-clinical-outcomes-following-surgical-scalpel-1c459f18acc6a61bPharmaRadar360en2026-09-13T00:00:00.000ZInfluence of gingival thickness on clinical outcomes following surgical scalpel depigmentation a prospective comparative clinical studyhttps://www.pharmaradar360.com/article/clinical-usability-of-an-explainable-ai-decision-support-tool-and-evaluation-of-f5c3a6def263501aPharmaRadar360en2026-09-13T00:00:00.000ZClinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLChttps://www.pharmaradar360.com/article/the-efficacy-and-safety-of-celecoxib-for-postoperative-pain-in-major-orthopedic-c41f40b2e490fa69PharmaRadar360en2026-09-13T00:00:00.000ZThe efficacy and safety of celecoxib for postoperative pain in major orthopedic surgery: a systematic review and pairwise meta-analysishttps://www.pharmaradar360.com/article/age-dependent-performance-of-conventional-trauma-scores-in-older-trauma-patients-df5cb966635b6338PharmaRadar360en2026-09-13T00:00:00.000ZAge-dependent performance of conventional trauma scores in older trauma patients: A retrospective trauma registry studyhttps://www.pharmaradar360.com/article/real-world-effectiveness-of-telitacicept-in-ebv-seropositive-patients-with-syste-fe93f7a17f0003a4PharmaRadar360en2026-09-13T00:00:00.000ZReal-world effectiveness of telitacicept in ebv-seropositive patients with systemic lupus erythematosushttps://www.pharmaradar360.com/article/multimodal-analysis-of-dental-radiographs-and-clinical-data-for-cardiovascular-r-13110790ce722d04PharmaRadar360en2026-09-13T00:00:00.000ZMultimodal Analysis of Dental Radiographs and Clinical Data for Cardiovascular Risk Stratification: A Review and Architecture Proposalhttps://www.pharmaradar360.com/article/construction-of-a-large-scale-biomedical-corpus-for-nlp-based-clinical-evidence-66d27e28a834d045PharmaRadar360en2026-09-13T00:00:00.000ZConstruction of a Large-Scale Biomedical Corpus for NLP-Based Clinical Evidence Retrieval Systemshttps://www.pharmaradar360.com/article/prophylactic-home-based-exercises-during-radiotherapy-in-head-and-neck-cancer-a-22d5403dc9d4314fPharmaRadar360en2026-09-13T00:00:00.000ZProphylactic Home‐Based Exercises During Radiotherapy in Head and Neck Cancer: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/the-femoral-impingement-index-predicts-inferior-clinical-outcomes-in-men-undergo-d48f8a53f53a1bb0PharmaRadar360en2026-09-13T00:00:00.000ZThe Femoral Impingement Index Predicts Inferior Clinical Outcomes in Men Undergoing Hip Arthroscopy for Femoroacetabular Impingement Syndromehttps://www.pharmaradar360.com/article/a-case-of-a-40-year-old-female-with-speech-disturbance-2192f4e6b9718ab9PharmaRadar360en2026-09-13T00:00:00.000ZA Case of a 40‐year‐old Female with Speech Disturbancehttps://www.pharmaradar360.com/article/gc-biopharma-gets-phase-2-approval-for-covid-19-vaccine-bfab50deecd04760PharmaRadar360en2026-09-12T23:26:32.000ZGC Biopharma Gets Phase 2 Approval for COVID-19 Vaccinehttps://www.pharmaradar360.com/article/samsung-bioepis-named-top-job-creating-company-eb946f6413a4e87aPharmaRadar360en2026-09-12T23:26:31.000ZSamsung Bioepis Named Top Job-Creating Companyhttps://www.pharmaradar360.com/article/gsk-s-adc-lays-down-marker-for-lung-cancer-scrap-with-merck-d370de291343afb9PharmaRadar360en2026-09-12T22:57:29.000ZGSK’s ADC lays down marker for lung cancer scrap with Merckhttps://www.pharmaradar360.com/article/veraxa-biotech-ag-stock-price-vrxa-stock-chart-market-cap-news-today-4961193ae7b32abdPharmaRadar360en2026-09-12T22:56:23.000ZVeraxa Biotech AG Stock Price: VRXA Stock Chart, Market Cap & News Todayhttps://www.pharmaradar360.com/article/eli-lilly-makes-another-biotech-bet-ahead-of-retatrutide-data-lly-stock-surges-t-f277b743c44c8524PharmaRadar360en2026-09-12T22:18:56.000ZEli Lilly Makes Another Biotech Bet Ahead Of Retatrutide Data – LLY Stock Surges To Highest In Over 2 Monthshttps://www.pharmaradar360.com/article/adio-signs-strategic-deal-with-german-biotech-company-bayer-ac2bbec6d7c144abPharmaRadar360en2026-09-12T22:02:13.000ZADIO signs strategic deal with German biotech company Bayerhttps://www.pharmaradar360.com/article/germantown-s-seraxis-announces-merger-to-form-diabetes-focused-biotech-company-040970b898a6533aPharmaRadar360en2026-09-12T22:00:27.000ZGermantown’s Seraxis Announces Merger to Form Diabetes-Focused Biotech Companyhttps://www.pharmaradar360.com/article/danish-pharmaceutical-novo-nordisk-introduces-ozempic-wegovy-drugs-in-kenya-eea7db5abbecd051PharmaRadar360en2026-09-12T21:12:54.000ZDanish pharmaceutical Novo Nordisk introduces Ozempic, Wegovy drugs in Kenyahttps://www.pharmaradar360.com/article/gc-wellbeing-bets-on-fat-shot-and-mounjaro-tie-up-to-drive-korea-growth-chosunbi-860f3872c5cae300PharmaRadar360en2026-09-12T21:00:00.000ZGC Wellbeing bets on fat-shot and Mounjaro tie-up to drive Korea growth - CHOSUNBIZhttps://www.pharmaradar360.com/article/medpacto-trials-revive-deal-prospects-as-theragen-etex-weighs-holding-stake-chos-d0c51f66ec7b502dPharmaRadar360en2026-09-12T21:00:00.000ZMedPacto trials revive deal prospects as Theragen Etex weighs holding stake - CHOSUNBIZhttps://www.pharmaradar360.com/article/cancer-drug-hand-foot-syndrome-risks-mapped-in-huge-fda-analysis-238ae56f04af0703PharmaRadar360en2026-09-12T20:58:11.000ZCancer Drug Hand-Foot Syndrome Risks Mapped in Huge FDA Analysishttps://www.pharmaradar360.com/article/pharmaceutical-speakers-the-complete-guide-to-find-book-hire-a-keynote-for-corpo-8a1ec198d20550d6PharmaRadar360en2026-09-12T20:33:06.000ZPHARMACEUTICAL SPEAKERS: THE COMPLETE GUIDE TO FIND, BOOK & HIRE A KEYNOTE FOR CORPORATE EVENTShttps://www.pharmaradar360.com/article/pharmaceutical-supply-chains-urged-to-begin-ndc-12-transition-planning-immediate-6e46cc9019edde23PharmaRadar360en2026-09-12T20:30:13.000ZPharmaceutical Supply Chains Urged To Begin NDC-12 Transition Planning Immediatelyhttps://www.pharmaradar360.com/article/trial-setback-might-change-the-case-for-investing-in-ultragenyx-stock-rare-3e2680d41502b831PharmaRadar360en2026-09-12T19:29:43.000ZTrial Setback Might Change The Case For Investing In Ultragenyx Stock (RARE)https://www.pharmaradar360.com/article/why-your-ndc-12-roadmap-should-start-now-01536b53d86921d0PharmaRadar360en2026-09-12T19:29:05.000ZWhy Your NDC-12 Roadmap Should Start Nowhttps://www.pharmaradar360.com/article/cms-s-hemp-cbd-program-has-a-physician-problem-mmj-appeal-pending-44ea6724fd164998PharmaRadar360en2026-09-12T19:23:17.000ZCMS's Hemp CBD Program Has A Physician Problem - MMJ Appeal Pendinghttps://www.pharmaradar360.com/article/donald-trump-talked-about-a-united-ireland-in-dublin-not-the-september-29-pharma-471e8e5510cb1b5fPharmaRadar360en2026-09-12T19:07:06.000ZDonald Trump talked about a united Ireland in Dublin, not the September 29 pharma deadlinehttps://www.pharmaradar360.com/article/china-s-plan-to-leap-ahead-in-race-for-next-big-weight-loss-drug-f45ef54de9ee97d7PharmaRadar360en2026-09-12T19:04:42.000ZChina’s plan to leap ahead in race for next big weight-loss drughttps://www.pharmaradar360.com/article/outsourcing-formulation-activities-may-advance-drug-development-5944d75d5ad4da59PharmaRadar360en2026-09-12T18:04:21.000ZOutsourcing Formulation Activities May Advance Drug Developmenthttps://www.pharmaradar360.com/article/fda-cdc-confirm-cyclosporiasis-outbreak-linked-to-taylor-farms-lettuce-under-con-c3bf319fa3d66a29PharmaRadar360en2026-09-12T18:02:58.000ZFDA, CDC confirm cyclosporiasis outbreak linked to Taylor Farms lettuce under control.https://www.pharmaradar360.com/article/how-direxion-daily-pharmaceutical-medical-bull-3x-shares-pill-affects-rotational-37342cd9f0425108PharmaRadar360en2026-09-12T18:02:02.000ZHow Direxion Daily Pharmaceutical & Medical Bull 3x Shares (PILL) Affects Rotational Strategy Timinghttps://www.pharmaradar360.com/article/mumbai-news-live-updates-maharashtra-fda-crackdown-paneer-khoya-curd-butter-wort-e460d700b4c871eePharmaRadar360en2026-09-12T17:56:00.000ZMumbai News LIVE Updates: Maharashtra FDA crackdown; Paneer, khoya, curd, butter worth Rs 4.45 crore seizedhttps://www.pharmaradar360.com/article/rfk-jr-says-fda-will-act-on-petition-to-reexamine-some-ingredients-in-ultra-proc-612c000bde7480b5PharmaRadar360en2026-09-12T17:46:06.000ZRFK Jr. says FDA will 'act on' petition to reexamine some ingredients in ultra-processed foodshttps://www.pharmaradar360.com/article/federal-bill-would-give-fda-approved-botanical-drugs-12-years-of-market-exclusiv-e80660ca90099e5bPharmaRadar360en2026-09-12T17:23:50.000ZFederal Bill Would Give FDA-Approved Botanical Drugs 12 Years of Market Exclusivity, With Potential Cannabis Implicationshttps://www.pharmaradar360.com/article/mbrx-stock-drops-25-as-moleculin-biotech-s-interim-cancer-trial-data-falls-short-d8f025f87aa6b36fPharmaRadar360en2026-09-12T17:12:35.000ZMBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significancehttps://www.pharmaradar360.com/article/cathie-wood-s-biotech-bet-intellia-secured-an-fda-priority-review-for-rare-genet-5f7c852de259bb0ePharmaRadar360en2026-09-12T17:11:13.000ZCathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platformhttps://www.pharmaradar360.com/article/etfs-investing-in-cabio-biotech-wuhan-co-ltd-class-a-stocks-a33d8632bf3d3697PharmaRadar360en2026-09-12T17:07:04.000ZETFs Investing in CABIO Biotech (Wuhan) Co. Ltd. Class A Stockshttps://www.pharmaradar360.com/article/ai-cyber-outer-space-biotech-critical-tech-shaping-opportunities-of-future-cbcbdcf9f3438d5cPharmaRadar360en2026-09-12T16:40:54.000ZAI, Cyber, Outer Space, Biotech, Critical Tech Shaping Opportunities Of Futurehttps://www.pharmaradar360.com/article/sls-ibrx-eye-green-month-as-biotech-etf-gains-steam-analyst-sees-continued-oppor-6a1aa66cf3396998PharmaRadar360en2026-09-12T16:40:01.000ZSLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncologyhttps://www.pharmaradar360.com/article/phase-3-emerald-3-trial-stride-lenvatinib-plus-tace-in-embolization-eligible-hcc-d89f76dc4e0b7264PharmaRadar360en2026-09-12T16:27:47.000ZPhase 3 EMERALD-3 Trial: STRIDE ± Lenvatinib Plus TACE in Embolization-Eligible HCChttps://www.pharmaradar360.com/article/5-biotech-stocks-with-highly-anticipated-pending-results-685f8dc34535c878PharmaRadar360en2026-09-12T16:18:16.000Z5 Biotech Stocks with Highly Anticipated Pending Resultshttps://www.pharmaradar360.com/article/promising-biotech-stocks-to-keep-an-eye-on-september-12th-efe64c7ece99109bPharmaRadar360en2026-09-12T16:07:30.000ZPromising Biotech Stocks To Keep An Eye On - September 12thhttps://www.pharmaradar360.com/article/perioperative-immunotherapy-more-than-doubles-event-free-survival-in-early-stage-583f131177b9b417PharmaRadar360en2026-09-12T16:07:06.000ZPerioperative Immunotherapy More Than Doubles Event-Free Survival in Early-Stage Lung Cancerhttps://www.pharmaradar360.com/article/mumbai-ganesh-mandals-cancel-mahaprasad-over-fda-rules-15dff49a023b8fefPharmaRadar360en2026-09-12T15:11:53.000ZMumbai Ganesh Mandals Cancel Mahaprasad Over FDA Ruleshttps://www.pharmaradar360.com/article/biotech-stocks-need-a-shot-in-the-arm-after-brutal-july-could-astrazeneca-bristo-0c28c1010a46e800PharmaRadar360en2026-09-12T14:36:31.000ZBiotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?https://www.pharmaradar360.com/article/an-officer-may-come-and-go-but-a-trustworthy-institution-must-endure-says-tukara-a4fd43de647a7b40PharmaRadar360en2026-09-12T14:30:37.000Z“An officer may come and go, but a trustworthy institution must endure,” says Tukaram Mundhe on Xhttps://www.pharmaradar360.com/article/this-small-cap-biotech-is-having-its-best-week-in-a-month-here-s-what-s-driving-681ea6d29eda7205PharmaRadar360en2026-09-12T14:26:18.000ZThis Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving Ithttps://www.pharmaradar360.com/article/antibody-drug-conjugate-hits-recommended-phase-3-dose-in-egfr-mutated-lung-cance-2e7532b9f25e2b0cPharmaRadar360en2026-09-12T14:22:04.000ZAntibody-Drug Conjugate Hits Recommended Phase 3 Dose in EGFR-Mutated Lung Cancerhttps://www.pharmaradar360.com/article/strata-mental-health-solutions-receives-compass-pathways-grant-for-comp360-provi-5e7e3f29061c4e4ePharmaRadar360en2026-09-12T13:56:35.000ZStrata Mental Health Solutions Receives Compass Pathways Grant For COMP360 Provider Traininghttps://www.pharmaradar360.com/article/maharashtra-fda-festive-crackdown-sweets-paneer-khoya-curd-butter-worth-rs-4-45-ca252589de5b56efPharmaRadar360en2026-09-12T13:48:00.000ZMaharashtra FDA festive crackdown: Sweets, paneer, khoya, curd, butter worth Rs 4.45 crore seizedhttps://www.pharmaradar360.com/article/can-fite-publishes-peer-reviewed-article-on-piclidenoson-and-namodenoson-potenti-0af5a6d68d575775PharmaRadar360en2026-09-12T13:47:44.000ZCan-Fite publishes peer-reviewed article on Piclidenoson and Namodenoson potentialhttps://www.pharmaradar360.com/article/trump-drug-pricing-deals-and-policy-uncertainty-create-unreadable-market-landsca-049be17091ba1587PharmaRadar360en2026-09-12T13:36:49.000ZTrump Drug Pricing Deals And Policy Uncertainty Create Unreadable Market Landscapehttps://www.pharmaradar360.com/article/fundly-ai-raises-4-9-million-to-expand-b2b-pharma-platform-c50ea0daee21a08bPharmaRadar360en2026-09-12T13:14:42.000ZFundly.ai Raises $4.9 Million to Expand B2B Pharma Platformhttps://www.pharmaradar360.com/article/technical-analysis-of-state-street-spdr-s-p-biotech-etf-cryptocom-xbiusd-p-251011cd265c51abPharmaRadar360en2026-09-12T13:06:29.000ZTechnical Analysis of State Street SPDR S&P Biotech ETF (CRYPTOCOM:XBIUSD.P)https://www.pharmaradar360.com/article/afghan-indian-officials-discuss-pharmaceutical-cooperation-b51c7c0a0b565719PharmaRadar360en2026-09-12T13:01:12.000ZAfghan, Indian officials discuss pharmaceutical cooperationhttps://www.pharmaradar360.com/article/evotec-stock-holds-near-52-week-low-as-revenue-drops-in-first-half-cef31d0bcd8eed64PharmaRadar360en2026-09-12T12:59:52.000ZEvotec stock holds near 52-week low as revenue drops in first halfhttps://www.pharmaradar360.com/article/b2b-pharma-platform-fundly-ai-raises-4-million-to-expand-commerce-payments-and-c-c143e24ddef24c12PharmaRadar360en2026-09-12T12:54:57.000ZB2B pharma platform Fundly.ai raises $4 million to expand commerce, payments and credit businesshttps://www.pharmaradar360.com/article/fda-gras-rule-would-require-notice-not-additive-approval-91e1ec2ab4df24bbPharmaRadar360en2026-09-12T12:51:35.000ZFDA GRAS Rule Would Require Notice, Not Additive Approvalhttps://www.pharmaradar360.com/article/abbvie-s-atogepant-delivers-positive-phase-3-results-in-menstrual-migraine-9b5b3859971b5d2ePharmaRadar360en2026-09-12T12:30:33.000ZAbbVie’s Atogepant delivers positive Phase 3 results in menstrual migrainehttps://www.pharmaradar360.com/article/should-debt-refinance-require-action-from-teva-teva-investors-85e0988c5562c871PharmaRadar360en2026-09-12T12:26:46.000ZShould Debt Refinance Require Action From Teva (TEVA) Investors?https://www.pharmaradar360.com/article/uzbekistan-health-agency-partex-ai-to-develop-digital-solutions-9f48d894eef80e20PharmaRadar360en2026-09-12T12:15:00.000ZUzbekistan Health Agency, Partex AI to Develop Digital Solutionshttps://www.pharmaradar360.com/article/india-joint-venture-partners-to-manufacture-pharmaceutical-products-in-moscow-ka-dc137a5820db4ea6PharmaRadar360en2026-09-12T12:03:03.000ZIndia Joint Venture Partners To Manufacture Pharmaceutical Products In Moscow & Kalugahttps://www.pharmaradar360.com/article/phase-1-study-supports-recommended-phase-3-dose-for-investigational-egfr-x-her3-9b4c556986e84b1dPharmaRadar360en2026-09-12T11:41:51.000ZPhase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancerhttps://www.pharmaradar360.com/article/uzbekistan-presents-pharmaceutical-products-in-south-korea-b84311811128667dPharmaRadar360en2026-09-12T11:30:00.000ZUzbekistan Presents Pharmaceutical Products in South Koreahttps://www.pharmaradar360.com/article/astrazeneca-s-breast-cancer-drug-etcamah-fails-serena-4-trial-4c465fc11872fde1PharmaRadar360en2026-09-12T11:16:36.000ZAstraZeneca's Breast Cancer Drug Etcamah Fails SERENA-4 Trialhttps://www.pharmaradar360.com/article/zhu-baoguo-founder-of-taitai-oral-liquid-steps-down-as-chairman-of-two-chinese-l-33a6de160dc6d765PharmaRadar360en2026-09-12T10:35:00.000ZZhu Baoguo, founder of "Taitai Oral Liquid," steps down as chairman of two Chinese listed pharma companies on the same day, formally retiring at 64https://www.pharmaradar360.com/article/azerbaijan-s-pharmaceutical-spending-rises-nearly-22-42364ddbd6b7dcf1PharmaRadar360en2026-09-12T10:32:15.000ZAzerbaijan's pharmaceutical spending rises nearly 22%https://www.pharmaradar360.com/article/eu-court-adviser-backs-challenge-to-pharmaceutical-wastewater-charges-f5177be301b558f1PharmaRadar360en2026-09-12T09:38:09.000ZEU court adviser backs challenge to pharmaceutical wastewater chargeshttps://www.pharmaradar360.com/article/fda-warns-public-against-unregistered-tirzepatide-product-874e29e432742269PharmaRadar360en2026-09-12T09:24:03.000ZFDA warns public against unregistered tirzepatide producthttps://www.pharmaradar360.com/article/mesoblast-completes-phase-3-trial-dosing-for-chronic-back-pain-therapy-663a24f4517ade40PharmaRadar360en2026-09-12T09:09:21.000ZMesoblast completes Phase 3 trial dosing for chronic back pain therapyhttps://www.pharmaradar360.com/article/cyprus-tip-off-led-to-greek-raid-on-illegal-drug-laboratory-linked-to-mazonakis-5f9d99378c2c09f4PharmaRadar360en2026-09-12T09:04:24.000ZCyprus tip-off led to Greek raid on illegal drug laboratory linked to Mazonakis casehttps://www.pharmaradar360.com/article/100-million-investment-plan-clears-way-for-bigger-pivot-park-176bf58aa84aed4bPharmaRadar360en2026-09-12T08:55:59.000Z€100 million investment plan clears way for bigger Pivot Parkhttps://www.pharmaradar360.com/article/advanced-breast-cancer-drug-fails-key-clinical-trial-days-after-regulatory-appro-098d437bd645687dPharmaRadar360en2026-09-12T08:50:01.000ZAdvanced Breast Cancer Drug Fails Key Clinical Trial Days After Regulatory Approvalhttps://www.pharmaradar360.com/article/national-pension-service-acquires-112-357-shares-of-teva-pharmaceutical-industri-260337801488a062PharmaRadar360en2026-09-12T08:37:55.000ZNational Pension Service Acquires 112,357 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/fifth-circuit-panel-hears-case-on-restricting-mail-order-abortion-pill-507d815126a994baPharmaRadar360en2026-09-12T08:30:00.000ZFifth Circuit Panel Hears Case on Restricting Mail Order Abortion Pillhttps://www.pharmaradar360.com/article/is-west-pharmaceutical-services-wst-cheap-following-its-recent-run-up-9d80bd8465e3c4d8PharmaRadar360en2026-09-12T08:23:35.000ZIs West Pharmaceutical Services (WST) Cheap Following Its Recent Run Up?https://www.pharmaradar360.com/article/comparing-healthcare-etfs-broad-vs-focused-exposure-516ea007c530dc21PharmaRadar360en2026-09-12T08:13:33.000ZComparing Healthcare ETFs: Broad vs. Focused Exposurehttps://www.pharmaradar360.com/article/relmada-s-ndv-01-bladder-cancer-trial-moves-into-phase-3-what-investors-should-w-6ae6a2ee7fa3d97ePharmaRadar360en2026-09-12T08:00:19.000ZRelmada’s NDV-01 Bladder Cancer Trial Moves Into Phase 3: What Investors Should Watchhttps://www.pharmaradar360.com/article/pakistan-pharma-industry-medicine-prices-drug-supply-pharmaceutical-policy-aaj-n-12b516d606ae7852PharmaRadar360en2026-09-12T07:00:19.000ZPakistan Pharma Industry | Medicine Prices | Drug Supply | Pharmaceutical Policy - Aaj Newshttps://www.pharmaradar360.com/article/pakistan-pharma-industry-medicine-prices-drug-supply-pharmaceutical-policy-aaj-n-ef0a623ac1e73cecPharmaRadar360en2026-09-12T07:00:16.000ZPakistan Pharma Industry | Medicine Prices | Drug Supply | Pharmaceutical Policy - Aaj Newshttps://www.pharmaradar360.com/article/fda-raids-11-thane-farsan-manufacturers-seizes-food-stock-worth-20-48-lakh-b5b76e392e3e4591PharmaRadar360en2026-09-12T06:57:49.000ZFDA raids 11 Thane farsan manufacturers, seizes food stock worth ₹20.48 lakhhttps://www.pharmaradar360.com/article/top-14-pharma-stocks-to-buy-in-india-september-2026-1ca08eb69cc1f994PharmaRadar360en2026-09-12T06:51:00.000ZTop 14 Pharma Stocks To Buy In India September 2026https://www.pharmaradar360.com/article/jpmorgan-initiates-dianthus-stock-at-overweight-135-target-by-investing-com-eeff66b407baecfdPharmaRadar360en2026-09-12T06:49:04.000ZJPMorgan initiates Dianthus stock at Overweight, $135 target By Investing.comhttps://www.pharmaradar360.com/article/china-accepts-ncx-470-nda-for-review-in-glaucoma-treatment-cfc222df1edb77f1PharmaRadar360en2026-09-12T06:44:07.000ZChina Accepts NCX 470 NDA for Review in Glaucoma Treatmenthttps://www.pharmaradar360.com/article/pune-fda-registration-mandatory-for-ganesh-mandals-distributing-prasad-fb8b05dd2f28ecd1PharmaRadar360en2026-09-12T06:36:22.000ZPune: FDA Registration Mandatory for Ganesh Mandals Distributing Prasadhttps://www.pharmaradar360.com/article/thai-fda-reports-over-52m-baht-peptide-haul-on-september-11-a6e10730598338f8PharmaRadar360en2026-09-12T06:21:00.000ZThai FDA reports over 52m-baht peptide haul on September 11https://www.pharmaradar360.com/article/dftx-vs-cmps-which-stock-has-more-upside-from-trump-s-new-psychedelic-therapy-pu-ef64dcf5e3960581PharmaRadar360en2026-09-12T06:05:32.000ZDFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?https://www.pharmaradar360.com/article/illegal-weight-loss-products-worth-b50-million-seized-e7dc688eef2fadddPharmaRadar360en2026-09-12T05:02:00.000ZIllegal weight-loss products worth B50 million seizedhttps://www.pharmaradar360.com/article/south-korea-s-drug-agency-lags-behind-1960s-fda-d3716d4263c37159PharmaRadar360en2026-09-12T04:52:24.000ZSouth Korea's Drug Agency Lags Behind 1960s FDAhttps://www.pharmaradar360.com/article/cmps-stock-clocks-muted-gains-but-analysts-back-psychedelic-drug-s-durability-ah-6a4a3cae17e5d82cPharmaRadar360en2026-09-12T04:28:05.000ZCMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filinghttps://www.pharmaradar360.com/article/frost-sullivan-presents-the-global-gene-therapy-crdmo-technology-innovation-lead-a3f7024e958c3afePharmaRadar360en2026-09-12T04:25:03.000ZFrost & Sullivan presents the “Global Gene Therapy Crdmo Technology Innovation Leadership Award” to PackGene Biotech Inc.https://www.pharmaradar360.com/article/acquired-hemophilia-a-clinical-trial-pipeline-gains-momentum-c128454433b644e0PharmaRadar360en2026-09-12T04:18:04.000ZAcquired Hemophilia A Clinical Trial Pipeline Gains Momentum:https://www.pharmaradar360.com/article/vietnam-vaccine-joint-stock-company-d68bb00762a34154PharmaRadar360en2026-09-12T04:17:00.000ZVietnam Vaccine Joint Stock Companyhttps://www.pharmaradar360.com/article/tracing-and-technology-at-the-food-and-drug-administration-fbfa4ab87a9c4f5cPharmaRadar360en2026-09-12T04:09:36.000ZTracing and Technology at the Food and Drug Administrationhttps://www.pharmaradar360.com/article/novartis-faces-a-reckoning-three-trial-failures-in-eight-days-test-the-limits-of-f4e0f13966bf3133PharmaRadar360en2026-09-12T03:50:49.000ZNovartis Faces a Reckoning: Three Trial Failures in Eight Days Test the Limits of Its Deal-Driven Grhttps://www.pharmaradar360.com/article/suspect-escapes-after-pursuit-following-drug-use-call-at-sequim-longhouse-6127b7b4572c5641PharmaRadar360en2026-09-12T03:38:13.000ZSuspect escapes after pursuit following drug-use call at Sequim longhousehttps://www.pharmaradar360.com/article/lady-gaga-and-michael-polansky-found-ai-biotech-company-77cc0d4530cd162bPharmaRadar360en2026-09-12T03:33:30.000ZLady Gaga And Michael Polansky Found AI Biotech Companyhttps://www.pharmaradar360.com/article/k-bio-firms-make-trillion-won-bets-to-secure-overseas-new-drugs-jkn-8615c51b08db3bfaPharmaRadar360en2026-09-12T03:30:00.000ZK-Bio Firms Make Trillion-Won Bets to Secure Overseas New Drugs : 건강 : JKNhttps://www.pharmaradar360.com/article/india-should-be-an-ai-powered-innovation-hub-and-not-just-a-low-cost-hub-dr-mahe-4c8e80ec418106a5PharmaRadar360en2026-09-12T03:29:59.000ZIndia should be an AI powered innovation hub and not just a low-cost hub: Dr Mahesh Bhalgathttps://www.pharmaradar360.com/article/pune-fda-seizes-paneer-from-four-trucks-in-budhwar-peth-ahead-of-ganeshotsav-cel-e9086992498407f7PharmaRadar360en2026-09-12T03:04:00.000ZPune: FDA seizes paneer from four trucks in Budhwar Peth ahead of Ganeshotsav celebrationshttps://www.pharmaradar360.com/article/journal-of-pharmaceutical-investigation-records-strong-citation-growth-with-5-5-690954f81d3094bfPharmaRadar360en2026-09-12T03:01:46.000ZJournal of Pharmaceutical Investigation Records Strong Citation Growth With 5.5 Impact Factor and Q1 Rankinghttps://www.pharmaradar360.com/article/abbv-stock-gains-on-winning-fda-approval-for-rare-blood-cancer-drug-1cabfd1aed67f747PharmaRadar360en2026-09-12T02:21:36.000ZABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drughttps://www.pharmaradar360.com/article/genscript-biotech-1548-hk-synthetic-expert-call-transcript-11-sep-2026-de67dd4d07cf5638PharmaRadar360en2026-09-12T02:19:58.000ZGenScript Biotech (1548 HK): Synthetic Expert Call Transcript (11 Sep 2026)https://www.pharmaradar360.com/article/pharmaceutical-company-expanding-adding-jobs-in-hauppauge-d80f5da0a5cd0868PharmaRadar360en2026-09-12T02:18:40.000ZPharmaceutical company expanding, adding jobs in Hauppaugehttps://www.pharmaradar360.com/article/hoth-s-pivot-from-biotech-to-space-tech-sparks-massive-rally-in-stock-retail-und-fea1a8d486dec34bPharmaRadar360en2026-09-12T01:58:22.000ZHOTH’s Pivot From Biotech To Space Tech Sparks Massive Rally In Stock – Retail Underlines Importance Of Securing Fresh Dealshttps://www.pharmaradar360.com/article/burning-rock-biotech-bnr-stock-rallies-while-losses-still-deepen-6fa40a99877d8199PharmaRadar360en2026-09-12T01:32:20.000ZBurning Rock Biotech (BNR) Stock Rallies While Losses Still Deepenhttps://www.pharmaradar360.com/article/sls-stock-snaps-2-day-slide-sellas-sls009-aml-trial-spotlights-big-pharma-drug-c-f36c0d0b6d235967PharmaRadar360en2026-09-12T01:29:51.000ZSLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMYhttps://www.pharmaradar360.com/article/biotech-startups-qualify-for-r-d-tax-credits-more-often-than-they-realize-k-38-c-99f5d2da9c4c0918PharmaRadar360en2026-09-12T01:20:02.000ZBiotech Startups Qualify for R&D Tax Credits More Often Than They Realize, K-38 Consulting Reportshttps://www.pharmaradar360.com/article/lilly-completes-ataibeckley-deal-adding-investigational-depression-pipeline-21206a1893121249PharmaRadar360en2026-09-12T01:00:53.000ZLilly completes AtaiBeckley deal, adding investigational depression pipelinehttps://www.pharmaradar360.com/article/biomarin-pharmaceutical-bmrn-posts-phase-3-win-and-fda-filing-in-hypochondroplas-ddd070aa04ad5d21PharmaRadar360en2026-09-12T00:52:05.000ZBioMarin Pharmaceutical (BMRN) Posts Phase 3 Win And FDA Filing In Hypochondroplasia